MX2021008834A - Metodos de tratamiento del cancer de mama con tucatinib. - Google Patents

Metodos de tratamiento del cancer de mama con tucatinib.

Info

Publication number
MX2021008834A
MX2021008834A MX2021008834A MX2021008834A MX2021008834A MX 2021008834 A MX2021008834 A MX 2021008834A MX 2021008834 A MX2021008834 A MX 2021008834A MX 2021008834 A MX2021008834 A MX 2021008834A MX 2021008834 A MX2021008834 A MX 2021008834A
Authority
MX
Mexico
Prior art keywords
tucatinib
breast cancer
methods
treating breast
treating
Prior art date
Application number
MX2021008834A
Other languages
English (en)
Spanish (es)
Inventor
Hao Sun
Luke Walker
Christopher J Endres
Anthony Jaeyong Lee
Ariel R Topletz-Erickson
Original Assignee
Seagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc filed Critical Seagen Inc
Publication of MX2021008834A publication Critical patent/MX2021008834A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2021008834A 2019-01-28 2020-01-24 Metodos de tratamiento del cancer de mama con tucatinib. MX2021008834A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962797854P 2019-01-28 2019-01-28
PCT/US2020/014953 WO2020159822A1 (en) 2019-01-28 2020-01-24 Methods of treating breast cancer with tucatinib

Publications (1)

Publication Number Publication Date
MX2021008834A true MX2021008834A (es) 2021-09-28

Family

ID=69740562

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008834A MX2021008834A (es) 2019-01-28 2020-01-24 Metodos de tratamiento del cancer de mama con tucatinib.

Country Status (13)

Country Link
US (1) US20220193076A1 (cg-RX-API-DMAC7.html)
EP (1) EP3917533A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022523045A (cg-RX-API-DMAC7.html)
KR (1) KR20210119498A (cg-RX-API-DMAC7.html)
CN (1) CN113613656A (cg-RX-API-DMAC7.html)
AR (1) AR119681A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020215551A1 (cg-RX-API-DMAC7.html)
CA (1) CA3126279A1 (cg-RX-API-DMAC7.html)
IL (1) IL284850A (cg-RX-API-DMAC7.html)
MX (1) MX2021008834A (cg-RX-API-DMAC7.html)
SG (1) SG11202107488PA (cg-RX-API-DMAC7.html)
TW (1) TW202042820A (cg-RX-API-DMAC7.html)
WO (1) WO2020159822A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
US20220125877A1 (en) * 2019-07-10 2022-04-28 Sun Yat-Sen University Method for treating colorectal cancer
IL301405A (en) * 2020-09-28 2023-05-01 Seagen Inc Methods for treating solid tumors driven by HER2 alterations with toctinib in combination with an anti-HER2 antibody
JP2024510435A (ja) 2021-03-18 2024-03-07 シージェン インコーポレイテッド 生体活性化合物の内部移行複合体からの選択的薬物放出
CN117243959B (zh) * 2022-10-13 2026-03-06 山东大学 治疗骨质疏松的方法和药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
WO1993017668A1 (en) 1992-03-12 1993-09-16 Alkermes Controlled Therapeutics, Inc. Controlled release acth containing microspheres
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
EP3615067A1 (en) * 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers

Also Published As

Publication number Publication date
SG11202107488PA (en) 2021-08-30
EP3917533A1 (en) 2021-12-08
CN113613656A (zh) 2021-11-05
JP2022523045A (ja) 2022-04-21
US20220193076A1 (en) 2022-06-23
CA3126279A1 (en) 2020-08-06
TW202042820A (zh) 2020-12-01
KR20210119498A (ko) 2021-10-05
AR119681A1 (es) 2022-01-05
IL284850A (en) 2021-08-31
WO2020159822A1 (en) 2020-08-06
AU2020215551A1 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12021550152A1 (en) Anti-cd112r compositions and methods
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
JOP20180039A1 (ar) مثبطات pd-1/pd-l1
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
ZA201905488B (en) Tigit- and light-based chimeric proteins
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
PH12022550646A1 (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
MY203971A (en) Anti-lag-3 antibodies and compositions
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
MX2021005398A (es) Terapia del cancer con celulas inmunitarias anti-cd33.
PH12016501680B1 (en) Anti-egfrviii antibodies and uses thereof
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
WO2020055643A3 (en) Compounds, compositions and methods for treating or preventing her-driven cancers
ZA202309516B (en) Anti-ccr8 antibodies
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
BR112022012867A2 (pt) Tratamento de câncer com inibidores de cdk12/13
AR119681A1 (es) Métodos de tratamiento del cáncer de mama con tucatinib
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.